1. Home
  2. LZM vs RLMD Comparison

LZM vs RLMD Comparison

Compare LZM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

N/A

Current Price

$4.24

Market Cap

387.9M

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$4.26

Market Cap

348.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LZM
RLMD
Founded
2021
2004
Country
Isle of Man
United States
Employees
93
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
387.9M
348.8M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
LZM
RLMD
Price
$4.24
$4.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$8.63
★ $10.75
AVG Volume (30 Days)
576.1K
★ 1.6M
Earning Date
07-29-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 45.28
EPS
★ N/A
N/A
Revenue
N/A
★ $13,070.00
Revenue This Year
$182.86
N/A
Revenue Next Year
$16.56
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$2.95
$3.07
52 Week High
$6.40
$8.00

Technical Indicators

Market Signals
Indicator
LZM
RLMD
Relative Strength Index (RSI) 58.28 59.22
Support Level $3.79 $4.19
Resistance Level $4.17 $4.53
Average True Range (ATR) 0.35 0.36
MACD 0.08 0.09
Stochastic Oscillator 68.75 66.78

Price Performance

Historical Comparison
LZM
RLMD

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: